Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
Globe Newswire•02/11/2026•08:00 ET
0
Key Highlights
- ➤Humacyte will release third-quarter and nine-month 2026 financial results November 10
- ➤Management will host an 8:00 a.m. Eastern webcast and conference call
- ➤FDA approved Symvess for vascular trauma in December 2024
- ➤Humacyte’s ATEVs remain in late-stage trials for hemodialysis access and peripheral artery disease
DURHAM, N.C, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the three months and nine months ended September 30, 2026, on Tuesday, November 10, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.
TitleHumacyte 2026 Third Quarter Financial Results and Corporate Update
Get started
Create a free account to read the full story.